Tiedemann Advisors’s Biogen BIIB Stock Holding History

Tiedemann Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-848	Closed	-$300K	–	425
2018 Q3	$300K	Buy	+848	New	+$292K	0.02%	258
2017 Q2	–	Sell	-1,148	Closed	-$314K	–	444
2017 Q1	$314K	Buy	+1,148	New	+$325K	0.03%	319

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Tiedemann Advisors's BIIB Position: Q4 2018 in Review

Tiedemann Advisors sold out of Biogen (BIIB) in Q4 2018, closing a stake of 848 shares — an estimated $300K sold.

Tiedemann Advisors first reported a position in BIIB in Q1 2017 and held it in 2 quarters. The position peaked at $314K in Q1 2017. 1,140 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

Tiedemann Advisors reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
Tiedemann Advisors sold 848 Biogen shares in Q4 2018, an estimated $300K.
Tiedemann Advisors first reported a position in Biogen in Q1 2017 and held it in 2 quarters.
Tiedemann Advisors's Biogen position peaked at $314K in Q1 2017.
1,140 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Tiedemann Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.